Two members of the House Energy and Commerce are pushing for insulin makers to explain why they have not lowered prices for the drug, despite the companies’ “expressions of shared concern” over prices. According to reporting in The Hill, Committee chair Frank Pallone Jr. (D-N.J.) and Diana DeGette (D-Colo.) expressed concern to the companies about “many” of the 34 million American diabetes patients left “without meaningful access to insulin due to its cost,” noting that insulin has not changed much since its production almost 100 years ago.
NCPA
